Lenacapavir PrEP implementation across 17 U.S. sites (n=501) was characterized by delays in initiation driven by payer processes. Early non-persistence was uncommon (3.6%) but exceeded clinical trial discontinuation rates and was strongly associated with abdominal injections and injection-site reactions requiring clinical contact, underscoring modifiable clinical and structural barriers to early persistence.
AH
Dr. Aniruddha Hazra
Infectious Disease · HIV & AIDS MedicineUniversity of Chicago Medical CenteraniruddhaChicago, IL, USA